---
schema_version: "secwatch.filing_event.v1"
accession: "0001096906-22-002280"
form_type: "8-K"
ticker: "AXIM"
cik: "0001514946"
company_name: "AXIM BIOTECHNOLOGIES, INC."
filed_at: "2022-09-19T23:59:59+00:00"
generated_at: "2026-06-23T08:48:27.869416+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AXIM signs exclusive global licensing deal with Verséa for dry eye diagnostic tests

## Summary
- Five-year License and Distribution Agreement with Verséa for global sale of AXIM's point-of-care ocular diagnostics.
- Three tests included: IgE (allergy), Lactoferrin (dry eye), and MMP-9 (inflammation); IgE and Lactoferrin are FDA-cleared.
- Verséa plans to launch IgE and Lactoferrin tests at 2022 AAO and Optometry conferences; MMP-9 in 18–24 months.
- Verséa must meet annual minimum sales commitments; no upfront or milestone payments disclosed.
- CEO Huemoeller says deal marks transition from development-stage to revenue-generating healthcare organization.

## SEC filing metadata
- accession: 0001096906-22-002280
- form_type: 8-K
- ticker: AXIM
- cik: 0001514946
- company_name: AXIM BIOTECHNOLOGIES, INC.
- filed_at: 2022-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514946/000109690622002280/0001096906-22-002280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514946/000109690622002280/axim-20210915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001096906-22-002280
- JSON: https://secwatch.observer/filing/0001096906-22-002280.json
- Plain text: https://secwatch.observer/filing/0001096906-22-002280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.